Conference Correspondent

Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

In a prior study, daratumumab (DARA) has demonstrated excellent clinical activity in combination with pomalidomide (POM) and dexamethasone (D) among relapsed or relapsed and refractory (R/RR) myeloma patients.1 While DARA is being evaluated in combination with other agents who are naïve to DARA or the backbone agent under evaluation, its utility is unclear among patients refractory to DARA or the combination agent.

This study evaluated 3 cohorts of patients receiving a combination of DARA-POM-D: cohort 1: patients naïve to both DARA and POM; cohort 2: patients refractory to DARA or POM; and cohort 3 (a subset of cohort 2): patients refractory to both DARA and POM. Researchers conducted a retrospective evaluation of 41 patients with relapsed or R/RR myeloma treated at a single site from January 2015 until July 2016.

Among the patients included in the analysis, the median age was comparable across cohorts at the time of DARA therapy initiation. All evaluable patients were lenalidomide-refractory, and 88% were bortezomib-refractory. Cohort 1 included 19 (46%) patients, cohort 2 included 22 (54%) patients, and cohort 3 included 12 (29%) patients. Median prior lines of therapy suggested that cohort 3 was a heavily pretreated group. High-risk cytogenetics for cohort 1:2:3 were 15.8% versus 31.8% versus 25%, respectively.

Common treatment-related adverse events (grade 3 or higher) included neutropenia (17 patients, 41%); anemia (12 patients, 29%); and thrombocytopenia (8 patients, 20%).

Patients in cohort 1 showed response rates of nearly 90%, and overall response rates of nearly 35% were seen in cohort 3. Progression-free survival was 7 months in all cohorts combined, and was 5 months in patients refractory to both DARA and POM (cohort 3). Notably, overall survival was 80% in cohort 3 after 8 months of follow-up.

These findings show that patients were able to recapture some of the response to agents to which they had become refractory, and lend support to further investigation of DARA-POM-DEX as a potential treatment option in heavily pretreated patients refractory to either or both DARA and POM.

Nooka AK, et al. ASH 2016. Abstract 492.

  1. Chari et al. ASH 2015.
Related Items
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Conference Correspondent published on December 2, 2016 in Conference Correspondent, ASH 2016 - Multiple Myeloma
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Conference Correspondent published on December 2, 2016 in Conference Correspondent, ASH 2016 - Multiple Myeloma
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
Conference Correspondent published on December 2, 2016 in Conference Correspondent, ASH 2016 - Multiple Myeloma
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Conference Correspondent published on December 2, 2016 in Conference Correspondent, ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Conference Correspondent published on December 2, 2016 in Conference Correspondent, ASH 2016 - Multiple Myeloma
Last modified: May 17, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME